ABSTRACT The study reports the effects on broiler performance of a newly isolated Bacillus subtilis strain, which is phylogenetically not closely related to already well-described strains of B. subtilis. In the first experiment, birds were reared in battery cages and exposed to C. perfringens. An increase in growth performance was observed with the strain when compared to the challenged animals. Three additional growth trials were conducted to 35 d of age, in different rearing conditions (genetic breeds, corn-soybean meal-based diet with or without animal proteins, in presence or absence of phytase, on fresh or used litter) to investigate the efficacy and the specificity of this new B. subtilis strain on the improvement of BWG and FCR of broilers in comparison with a B. subtilis-based DFM already used in the field. Whatever the rearing conditions tested, the new B. subtilis strain led to an average 3.2% improvement in feed conversion ratio or bodyweight. Comparatively, the commercial Bacillus strain significantly improved broiler performance in only one trial out of 3 with an average improvement reaching 2%. All these results indicate that this new B. subtilis strain consistently improves broiler performances.
INTRODUCTION
The concept of "gut health" is complex but it is now well recognized as a key driver of animal performance. As proposed by Conway, 1994 , gut health is based on a dynamic equilibrium of 3 components: diet, gut mucosa, and microbiota. A good practice management of gut health can help decrease the occurrence of infectious diseases and other digestive disorders, such as wet or poor litter, watery or sticky droppings and malabsorption, which all lead to huge economic losses (Choct, 2009) . In Europe, the ban of antibiotic growth promoters in 2006 increased the incidence of certain animal infectious diseases, such as necrotic enteritis (NE), resulting in high economic losses in the poultry industry (Wierup, 2001; Van Immerseel et al., 2004; Dibner and Richards, 2005; Gaucher et al., 2015; M'Sadeq et al., 2015) and to the strong needs to find alternatives.
Among alternatives, probiotics are defined as "live microorganisms that, when consumed in adequate amounts, confer a health benefit on the host" (FAO/WHO, 2002) . Several studies have reported the positive impact of probiotics on intestinal microbiota, growth performance, and feed efficiency in broiler chickens (Ahmad, 2006; Mountzouris et al., 2007; Awad C et al., 2009) . However, the literature shows that their efficacy is variable and can depend on numerous parameters: the probiotic species and strain, its stability, the breeding environment, the management of the probiotic use (administration route, time, and dosage), and the genetic, age, and health status of the animals (Otutumi et al., 2012) .
Among the wide variety of probiotics used in poultry production are strains belonging to Lactobacillus, Enterococcus, Bifidobacterium, Lactococcus, Streptococcus, Pediococcus, and Bacillus genera as well as E. coli and a range of yeast species (Patterson and Burkholder, 2003; Mountzouris et al., 2007; Lutful Kabir, 2009 ). The ability of Bacillus species to form endospores, which are stable to passage of the stomach, bile salts, and chemical and physical stresses and that also allow pelleting and storage over a long time, makes them very attractive for use in animal feed. In poultry production, different strains of Bacillus subtilis, Bacillus amyloliquefaciens, and Bacillus licheniformis have been used for several years (Cutting, 2011) . Even within Bacillus strains, the large variability of the efficacy obtained underlines the importance of the sourcing and the screening process to select an effective probiotic strain with proven efficiency in a large range of conditions.
In this study, we report the effects of a newly isolated Bacillus subtilis strain, which is phylogenetically not closely related to already well-described strains of B. subtilis, on broiler performances in different conditions of growth. 
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MATERIALS AND METHODS
Phylogeny Study
Sequencing and phylogenetic analysis of B. subtilis DSM29784, a bacterium from the private collection of Novozymes, and of the commercial B. subtilis Bs A was based on the gyrB gene and done essentially as described by Wang et al. (2007) . The sequences of the gyrB genes of the reference strains (listed in Table 1) were retrieved from the EMBL database. The sequences were aligned using the ClustalW, and a phylogenetic tree was made based on distance matrix calculated with the Kimura distance formula using MegAlign (default settings, DNA STAR 7, Lasergene vers. 7.2.1) (Figure 1) .
In vivo C. Perfringens (Cp) Model to Select a Novel Strain of B. Subtilis
A total of 256 one-day-old Cobb x Cobb male broiler chicks was housed in battery cages (8 birds each) and allocated according to a randomized complete block design with 8 blocks and 4 treatments per block. The experimental treatment groups consisted of 1) control (non-Cp exposed, non-supplemented), 2) Cp exposed and non-supplemented, 3) Cp exposed + bacitracin methylene disalicylate (BMD) at 55 ppm, and 4) Cp exposed + Bacillus subtilis DSM29784 at 5.10 8 CFU/kg of feed. The diet used was a non-supplemented commercial corn-soybean meal diet (Table 2 ). Feed and water were available ad libitum throughout the trial. On d 14, all birds were orally administered with a coccidial inoculum containing approximately 5,000 oocysts of Eimeria maxima per bird. Once daily on d 19, 20, and 21, all birds, except the control group, were administered (by oral gavage) one mL of a fresh broth culture of C. perfringens (10 8 CFU/mL). The live body weight and the feed consumption were recorded at the start (d one) and the end of the experiment (d 28), on a cage basis, to calculate performances: feed intake (FI), body weight gain (BWG), and feed conversion ratio (FCR). Global mortality was recorded daily and the FCR was adjusted accordingly. The protocol of this experiment followed the Southern Poultry Research, Inc. ethical review process and was approved by SPR Institutional Animal Care and Use Committee. 
Performance Trials
Three broiler performance studies were conducted in 3 different research facilities in order to test different experimental diets, environments, and broiler breeds. Design was the same for all studies, with 3 treatments, CON: control group fed with a basal diet; Bs A: group fed with a basal diet supplemented with a commercial Bacillus subtilis strain (at 8.10
8 CFU/kg of feed from d one to d 35); and Bs DSM29784: a group fed with a basal diet supplemented with the Bacillus subtilis strain DSM29784 (at 5.10 8 CFU/kg of feed from d one to d 35).
The diets were similar among the studies and based on corn-soybean meal. Nutrient levels were calculated to meet or exceed requirements of the animals, according to breeder recommendations (Table 3 ). All experimental diets included vitamin and mineral premixes, but did not contain any coccidiostat, NSPase, or growth-promoting substances. Feed and water were available ad libitum throughout the trial.
The 3 studies differed by the broiler breed used, the presence or absence of animal by-products and of phytase in the diets, the experimental design, and the litter condition (Table 4) .
All experiments have been conducted in accordance with the experimental unit policy on animal welfare and the requirements of the corresponding national legislation.
Experimental Design of Each Study
Trial 1. A total of 540 one-day-old male Ross 708 broiler chickens was individually weighed (body weight 47.1 g ± 1.1 g) and allocated in floor pens (15 birds/pens) with used litter. Pens were used in a factorial and completely randomized design with 12 pens per treatment (i.e., 180 animals/treatment). Trial 2. A total of 648 one-day-old male Ross PM3 broiler chickens was individually weighed (body weight 42 g ± 3.5 g) and allocated in floor pens (18 birds/pens) with fresh litter. Pens were used in a factorial and completely randomized design with 12 pens per treatment (i.e., 216 animals/treatment). Basal diets consisted of a 2-phase feeding program: starter phase (d one to d 21) and grower phase (d 22 to d 35).
Trial 3. A total of 1,200 one-day-old male Cobb 500 broiler chickens was individually weighed (body weight 42 g ± 1 g) and allocated in floor pens (50 birds/pen) with used litter. Pens were used in a factorial and completely randomized design with 8 pens per treatment (i.e., 400 animals/treatment). In each trial, BWG, FI, and FCR, corrected for mortality, were measured on a pen basis at d one, d 21, and d 35.
Statistical Analysis
For the challenge study, the raw data have been analysed using the STATIX program LSD test and cages as experimental unit. P-value 0.05 has been used to separate means when ANOVA values were significant (P ≤ 0.05).
Raw data from the growth studies were subjected to ANOVA, with block and treatment as fixed effects using the ANOVA procedure of XLSTAT to establish differences among diets. Pen was considered as the experimental unit. Results are reported as least square means. LS means were assumed to be different at P ≤ 0.05. Mortality within experiments was analyzed with the Chi-square test.
RESULTS
Phylogeny
The gyrB gene sequence analysis showed that B. subtilis DSM29784 is different from the type strain of B. subtilis at a level similar to the already known and described subspecies, B. subtilis subsp. spizizenii and B. subtilis subsp. Inaquosorum (Figure 1 ). Whereas the other strain of interest in our study, the commercial B. subtilis strain (Bs A), showed close relatedness to the type strain of B. subtilis subsp. subtilis, the novel isolated strain is different from the existing subspecies of B. subtilis (subsps. inaquosorum and spizizenii) at approximately the same level as to subsp. subtilis.
Study Under in Vivo Cp Exposure
Results are summarized in Table 5 . The exposure to C. perfringens in this in vivo model was successful as shown by the decrease of BWG and FCR (−16.1% and +19.2%, respectively) of the exposed and non-supplemented birds compared to the birds from the non-exposed and non-supplemented group. Animal mortality was also significantly affected (P < 0.01) reaching a level up to 42.5%. This total mortality level was reduced numerically only from 42.5 to 30% (ns) with DSM29784, whereas it was reduced significantly to 12.5% (P < 0.01) with BMD.
The main effect of DSM29784 was an improvement of performances (FCR and BWG) of Cp exposed animals. B. subtilis DSM29784 and BMD significantly (P < 0.01) improved FCR of Cp exposed animals by −0.212 and −0.175 points, respectively. BWG also was improved numerically with BMD (+85 g) and significantly (P < 0.01) with DSM29784 (+118 g). a-c Means within a row lacking a common superscript differ (P < 0.05). 1 BWG = body weight gain; FCR = feed conversion ratio. 2 Treatments: Non-Cp expl., nonsup. = non-Cp exposed and nonsupplemented; Cp exp., nonsup. = Cp exposed and non-supplemented; Cp exp., BMD = Cp exposed and supplemented with BMD at 55 ppm; Cp exp., DSM29784 = Cp exposed and supplemented with B. subtilis strain DSM29784 at 5.10 8 CFU/kg of feed.
Growth Performance Studies
Three animal studies were conducted and analyzed independently in order to investigate the specificity of B. subtilis strains, DSM29784 and the commercial strain, in term of effects on performance of broilers raised in different conditions. Results are presented in Table 6 .
Mortality levels were different among the trials, and were quite high in Trials 1 and 2. These high levels of mortality were probably due to the absence of medication, namely coccidiostat, in all of the trials. Interestingly, the effects of the 2 probiotic strains on mortality seemed different. In Trial 1, in the period of 22 to 35 d, DSM29784 decreased significantly the mortality whereas Bs A had no effect. In Trial 3, in the period of one to 21 d, whereas DSM29784 did not modify mortality rate, Bs A increased it.
During the starter phase, there was no effect of the B. subtilis strains on animal performance except in Trial 3 in which B. subtilis DSM29784 significantly (P < 0.05) improved the FCR by 3.0% compared to the control group.
During the grower phase, only B. subtilis DSM29784 had a significant effect on performance. Indeed, there was an increase of BWG (+3.6%, P < 0.05) in Trial 1, and an improvement of FCR in Trial 2 (−7.1%) for the animals receiving B. subtilis DSM29784, when compared to the control group.
Globally, the commercial B. subtilis strain had a positive effect on performance only in one trial (Trial 2) out of the 3 in which it significantly (P < 0.05) improved FCR (−3.4%). On average, in the 3 trials, the improvement of the performance with this strain was +1.7% and −2.1% for BWG and FCR, respectively.
In this same global period (d one to 35), B. subtilis DSM29784 significantly (P < 0.05) improved BWG in Trial 1 (+2.3%) and FCR in Trials 2 and 3 (+4.8 and 1.7%), respectively. These results indicate that B. subtilis DSM29784 is able to improve broiler performances in all the conditions tested here, with an average increase of +3.8% for the BWG, and −3.2% for the FCR.
DISCUSSION
The phylogenetic study of the gyrB presented here revealed that the Bacillus strain DSM29784 belongs to B. subtilis species, but is not closely related to the 3 well-characterized subspecies of B. subtilis. The B. subtilis DSM29784 shows between 93.1 and 94.7% identity to the type strains of the 3 existing subspecies of B. subtilis. In contrast to this, the already commercialized strain, Bs A, shows 98.7% identity to the B. subtilis subsp. subtilis. The type strains of the established B. subtilis subsps. inaquosorum, spizizenii and subtilis show from 94 to 96% similarity between them. Same level of differences (only 94.1% identity) also was observed between DSM29784 and Bs A, suggesting that these 2 strains are very different in phylogenetic terms.
Probiotics' mode of action is not yet fully understood but it is recognized that probiotics have direct and indirect effects on the microbiota composition and on the host, through their immunomodulatory properties (Hardy et al., 2013) . Stresses and life events can induce a shift in microbial community composition, often in favor of harmful bacteria leading to an immune imbalance, and/or an inflammatory response (Onrust et al., 2015) . Even slight changes in this host-microbiota interaction can lead to a disruption of gut health homeostasis, which can result in enteric diseases affecting overall performances (M'Sadeq et al., 2015) .
We tested the potential of B. subtilis DSM29784 to improve performances of animals exposed to a challenge. Looking at performance improvement, namely BWG and FCR, B. subtilis DSM29784 was able to restore performance of Cp exposed animals at a level similar to the effects of BMD.
In addition, 3 growth trials were conducted in experimental conditions differing mainly in feed composition (presence or absence of animal by-product) and rearing conditions (location and used vs. fresh litter). The level, source, and amino acid content of proteins in the diet were adjusted to predispose birds to enteric diseases or disorders (Kaldhusdal and Skjerve, 1996; Wu et al., 2010; Wu et al., 2014) . Availability of indigestible proteins for proteolytic bacteria in the lower part of GIT and the subsequent production of unfavorable metabolites encourage proliferation of pathogenic bacteria such as Clostridium species (Lan et al., 2005; Timbermont et al., 2011) . In addition, rearing conditions, such as the litter condition also can affect gut health, and consequently animal performance. Poultry litter can act as a reservoir of exogenous bacteria, whose composition varies according to the litter management, and it can affect the GIT microbiota, thus challenging the birds even further (Lu et al., 2003; Wang et al., 2016) . Interestingly, in Trial 2, in which there were new litter and no animal by-products, both strains of B. subtilis were shown to be effective, suggesting that the conditions used in this trial were probably the most susceptible to changes in terms of digestive balance. Contrary to the commercial strain, B. subtilis DSM29784 also was able to significantly improve broiler performances in Trials 1 and 3. As a consequence, the selected strain presented the best average effect over the 3 different trials. Moreover, the results of this study show that the greatest response was not obtained in the birds exhibiting the lowest growth performance (Trial 3, 1,984 g at 35 d). Indeed, the similar increase in performance was obtained with the highest performing ones, 2,361 g at 35 d, gaining 2.3% more weight at 35 d with the probiotic (P < 0.05) and in the lowest performing ones (Trial 3, +2.1%, NS).
Our results also suggest the hypothesis that this new strain of B. subtilis, DSM29784, is not dependent on the microbial and health status of the broiler chickens. Testing the efficacy of B. subtilis DSM29784 in more experimental conditions, as well as studying more in details the microbiota composition and the host status of the birds, will certainly help us to understand its mode of action.
Finally, this study showed that 1) a probiotic strain can exert its beneficial effect on the host according to the rearing conditions, as reviewed by Otutumi et al. (2012) and 2) even if 2 strains belong to the same species, they can show different efficacy. The importance of strain specificity for probiotic effects in humans already has been demonstrated and stated, especially for Lactobacillus and Bifidobacterium-based probiotic (Rowland et al., 2010; Million and Raoult, 2013) . When considering effects of probiotics on poultry performance, there are a lot of reports on species specificities, such as studies comparing different species of B. subtilis (Wolfenden et al., 2010; Shivaramaiah et al., 2011) . But, in those reports, identification at the strain level is missing. This study confirms that the term "strain specificity" should not only include the strain identity, but also its specificity of action that might be a key point to achieve a consistent effect in broiler performance.
